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OBJECTIVES: RNA silencing utilizing short interferingRNA (siRNA) offers anewand exciting means to overcome the limitations
of current treatment options of many diseases. However, delivery of these molecules still poses a great challenge to date.
METHODS: In the present study, a multicompartmental biodegradable polymer-based nanoparticles-in-microsphere oral system
(NiMOS) using gelatin nanoparticles encapsulating a combination of siRNA duplexes speciﬁcally targeted against tumor necrosis
factor-a (TNF-a) and cyclin D1 (Ccnd1) was employed to study its effects on a dextran sulfate sodium (DSS)-induced acute colitis
mouse model mimicking inﬂammatory bowel disease (IBD). DSS colitis-bearing animals were divided into several control and
treatment groupsandreceived either no treatment, blankNiMOS, NiMOS-encapsulatinginactive(scrambled), active TNF-asilencing,
CyD1 silencing siRNA, or a combination of both active siRNAs by repeated oral administration of three NiMOS doses.
RESULTS: Successful gene silencing with the aid of dual siRNA treatment led to decreased colonic levels of TNF-a or CyD1,
suppressed expression of certain pro-inﬂammatory cytokines (interleukin-1a and -b, interferon-c), an increase in body weight,
and reduced tissue myeloperoxidase activity, while the silencing effect of CyD1 siRNA or the dual treatment was more potent
than that of TNF-a siRNA alone.
CONCLUSIONS: Results of this study demonstrate the therapeutic potential of a NiMOS-based oral combined TNF-a and CyD1
gene silencing system for the treatment of IBD as shown in an acute colitis model.
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INTRODUCTION
Crohn’s disease and ulcerative colitis constitute the two main
phenotypes of inﬂammatory bowel disease (IBD), a group of
clinical relapsing conditions of unknown etiology associated
with mucosal inﬂammation of the gastrointestinal tract.
1–3
Current treatment options involving the use of conventional
therapy, including anti-inﬂammatory and immunosuppressive
drugs,
4 have shown success in management of acute
inﬂammation, but could not effectively maintain remission
due to tolerability, toxicity, dependency, and higher relapse
rates
5 often leaving surgical removal of inﬂamed tissue as a
last resort, which poses physical pain and mental stress for
patients. To overcome shortcomings in efﬁcacy and safety,
novel treatment options include development of biological
therapies involving inhibition of mucosal inﬂammatory path-
waysbytargetingpro-inﬂammatorycytokines,theirreceptors,
and adhesion molecules, and thus offer more effective
treatment options for the disease.
6,7 Success has been
reported in biological therapies, especially in patients refrac-
tory to conventional treatment, using speciﬁc systemic
monoclonal antibodies or soluble receptors aimed at
neutralization and reduction of tumor necrosis factor-a
(TNF-a),
2,5,9–12 a pivotal cytokine in IBD that has a central
role in mediation of inﬂammatory responses.
13 However,
severe side effects and contraindications, such as opportu-
nistic infections, decreased efﬁcacy, and infusion reactions,
have frequentlybeen reported
10,11,14sothatother therapeutic
options have received a great deal of attention. One
alternative treatment strategy includes gene therapy, where
the gastrointestinal tract additionally poses an ideal starting
point and target due to its extremely large surface area and
access to luminal sites of inﬂammation via rectal and oral
routes of administration.
This study evaluates the potential of RNA interference
(RNAi) as an alternative treatment forsystemic diseases such
as IBD. Hereby, short interfering RNA (siRNA), which
is usually composed of double-stranded 20–25 nucleotides,
is associated with a gene silencing mechanism, which
interferes with the expression of a speciﬁc gene, e.g., one
that is overexpressed in a certain disease.
15 To date, many
studies explore the potential of RNAi in cancer therapy,
16–18
whereasveryfewfocusonthetreatmentofinﬂammation.
19–22
RNAi offers great potential for the development of novel
drugs. However, one of the biggest hurdles remains in safe
and efﬁcacious delivery of siRNA to the organ and cells of
interest to avoid degradation of the payload and increase in
residence time to allow for sufﬁcient interaction with cells and
a resulting cellular uptake to occur. As such, development of
proper delivery and encapsulation techniques, including viral
vectors,
23 nanoparticles,
21,24 and polymer-based
22,25,26 and
liposome-basedvehicles,
15,19iscrucialinthesuccessofgene
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www.nature.com/ctgsilencing by siRNA. Further, systemic administration has
been investigated most commonly,
15,17,20,21 while very few
studies have been devoted to study mucosal delivery,
including rectal, vaginal,
19 or oral routes.
22
Nanoparticles-in-microsphere oral system (NiMOS) is a
multicompartmental delivery system speciﬁcally designed for
oral administration of nucleic acid contructs.
27–30 In previous
studies, we have shown that both reporter (i.e., enhanced
green ﬂuorescent protein expressing) and therapeutic (i.e.,
murine interleukin (IL)-10 expressing) plasmid DNA were
transfected in NiMOS administered orally to naı ¨ve and acute
colitis-bearing Balb/c mice.
28,30,31 Additionally, we recently
showed that TNF-a silencing siRNA, when encapsulated in
NiMOS, could be used for the treatment of IBD in dextran
sulfate sodium (DSS)-induced colitis-bearing Balb/c mice.
32
The speciﬁc purpose of the present study was to evaluate
the effect of dual siRNA delivery targeting multiple genes of
interest as a way to further improve the treatment of IBD.
To achieve this goal, we used NiMOS for encapsulation of
TNF-a- and cyclin D1 (Ccnd1)-speciﬁc siRNA in one formula-
tion, and evaluated dual gene silencing and therapeutic
efﬁcacy in DSS-induced colitis model of IBD. CyD1 is a
member of the cyclin family and key regulator during the cell
cycle by controlling the progression from G1 to S phase.
33–35
It is overexpressed in many human cancers
35–37 and
inﬂammatory diseases;
21,38,39 however, its exact role in
inﬂammation is not known yet. Because of its importance,
it serves as a potential target for treatment options of
inﬂammatory diseases such as IBD.
METHODS
Preparation of siRNA-encapsulated gelatin nanoparticles
and NiMOS. Nanoparticles were prepared from gelatin
(MW 40,000–50,000, 100–115mM of free carboxylic acid
per 100g of protein, pI of 4.7–5.2, 225 bloom strength) in the
same manner as described before.
27,29,31 In brief, siRNAs
were mixed with aqueous gelatin solutions of pH 7.0 and
pre-incubated for 10min at room temperature, followed by
controlled precipitation of siRNA-containing or blank gelatin
solutions by using ethanol as the non-solvent. Resulting
nanoparticles were centrifuged at 32,000r.p.m. for 45min,
puriﬁed, and lyophilized. Desalted and annealed siRNAs
were obtained from Dharmacon (Lafayette, CO), and their
sense sequences are shown in the Supplementary Table S1.
NiMOS were prepared with a ‘‘double emulsion-like’’ tech-
nique, which has been used previously by numerous other
researchers in our research laboratory
27,29,31 and is a
standard procedure for production of microparticulate
delivery systems in the pharmaceutical industry.
40,41
Characterization of siRNA-encapsulated gelatin nano-
particles and NiMOS. NiMOS consists of biocompatible
nucleic acid-encapsulated type B gelatin nanoparticles further
entrapped in a poly(e-caprolactone) microsphere (Figure 1).
Particle size analysis. The mean particle size of freshly
prepared nanoparticle formulations was determined with the
Malvern Zetasizer Nano ZS 90 apparatus (Westborough, MA)
at a 901 scattering angle. NiMOS was characterized for
particle size and size distribution using the Multisizer 3t from
Beckman Coulter (Fullerton, CA). All sizing measurements
were carried out at room temperature.
Scanning electron microscopy. Lyophilized blank or loaded
gelatin nanoparticles and NiMOS samples were sputter
coated with gold-palladium to minimize surface charging
and evaluated according to their surface morphology with a
Hitachi S-4800 (Pleasanton, CA) ﬁeld emission scanning
electron microscope.
Determination of siRNA loading in gelatin nanoparticles and
NiMOS. siRNA-loaded gelatin nanoparticles and NiMOS were
prepared as discussed above. Encapsulation efﬁciency of siRNA
in these formulations was determined by dissolving a known
amount of sample (B50mg) in phosphate-buffered saline (pH
7.4) containing 0.2mg/ml protease at 371C until a clear solution
was obtained. Released double-stranded siRNA was quantiﬁed
using the PicoGreens assay (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. The intensity of
ﬂuorescence, which is proportional to the PicoGreen-bound
siRNA was measured at an excitation of 485nm and emission of
520nm wavelengths using a Perkin Elmer LS50B spectro-
photometer (Waltham, MA). FL WinLabt (Perkin Elmer)
software was used for processing and analysis of resulting data.
For evaluation of siRNA loading in NiMOS, 100mg of sample
was added to 1ml dichloromethane to dissolve the poly(e-
caprolactone) matrix and liberate the gelatin nanoparticles. To
this organic poly(e-caprolactone)-dichloromethane mixture, an
equal amount of distilled deionized water was added. After
careful separation of the aqueous from the organic phase, gelatin
nanoparticles underwent the same procedure as described
above to measure the ﬁnal siRNA loading efﬁciency in the
NiMOS using the PicoGreen quantitation assay.
Animal model development and in vivo studies of gene
silencing and efﬁcacy
Experimental animals. All animal studies involved were
performed in accordance with the experimental protocol
Figure 1 Nanoparticles-in-microsphere oral system (NiMOS) for short
interfering RNA (siRNA) delivery. Schematic representation of the NiMOS concept
and scanning electron micrographs of siRNA-encapsulated type B gelatin
nanoparticles further entrapped in poly(e-caprolactone) microsphere.
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Committee at Northeastern University (Boston, MA).
Female Balb/c mice (6–8 weeks, B18–20g) were
purchased from Charles River Laboratories (Wilmington,
MA). Animals were randomly assigned to groups of 4–5 mice
per cage and acclimatized for 10 days before the start of the
study. The mice were housed in rooms at a controlled
temperature of 221C and 26% humidity, with light–dark
cycles of 12h, and fed with water and a standard pellet ad
libitum except when fasted overnight to prepare for the oral
gavage.
Induction of acute colitis using DSS. Animals were randomly
assigned to 14 groups (n¼4–5). Acute colitis was induced in
mice by addition of 3.5% (w/w) DSS (MW 36,000–50,000; MP
Biomedicals United States, Solon, OH) in their drinking
water for the duration of the study, whereas one control
group (n¼8) received regular tap water at the same time.
DSS solutions were freshly prepared daily and mice were
monitored every day for their health condition.
42 The acute
disease model was conﬁrmed by evaluation of weight loss,
stool consistency, rectal bleeding, and tissue histology. At
day 10 and 12 of the study, animals were sacriﬁced by CO2
inhalation followed by cervical dislocation, and tissue was
processed as described below.
Oral siRNA administration in DSS colitis-induced Balb/c
mice. On days 2, 4, and 6 of the study, mice of all groups
including controls were fasted overnight, followed by
administration of blank NiMOS (particles containing no
siRNA) or microparticles containing siRNA (inactive seq-
uence, TNF-a, CyD1, or a combination of TNF-a/CyD1) to
animals on days 3, 5, and 7 by oral gavage using a blunt-tipped
feeding needle inserted into the esophagus equaling three
doses of NiMOS formulations per group. An additional control
group, serving as DSS control, consisted of animals receiving
no oral treatment throughout the course of DSS exposure.
At predetermined time points of 3 and 5 days after the last
administration (day 10 and 12, respectively), 4–6 animals per
time point and group were killed. After euthanasia, the large
intestine was surgically removed and carefully washed with
phosphate-buffered saline for histological analysis of the
tissue sections and determination of cytokines, murine TNF-a
or CyD1 mRNA levels, and expression of CyD1 by Multiplex
enzyme-linked immunosorbent assay (ELISA), real-time
quantitative PCR (qPCR) and western blotting.
Isolation of RNA from colon tissue and qPCR. Tissue
samples were stored in RNAlater (Applied Biosystems,
Foster City, CA) at 41C for 2 days to allow for tissue
penetration, followed by removal of excess liquid and storage
of tissue at  701C until further processing. Subsequently,
RNA was isolated from colon tissue samples using the
RNAqueous-4PCR kit (Applied Biosystems) according to the
manufacturer’s protocol and quantiﬁed using the NanoDrop
1000 (Thermo Fisher Scientiﬁc, Wilmington, DE) UV–visible
spectrophotometer.
Reverse transcription of isolated RNA samples. A volume
corresponding to 1mg of RNA was used for the comple-
mentary DNA (cDNA) synthesis process using the
SuperScriptt III First-Strand Synthesis SuperMix for qRT-
PCR (Invitrogen) in accordance with the manufacturer’s
recommendation. Samples containing cDNA were diluted to
a ﬁnal volume of 100ml and used for subsequent real-time
qPCR.
Analysis by real-time qPCR. Real-time qPCR was performed
on cDNA samples obtained from large intestinal tissue to
determine the levels of mRNA transcript. L32 gene expressing
the L32 ribosomal protein served as a control. Pre-diluted
cDNA was mixed with 0.2mM of primer pair detecting the
murine TNF-a,m u r i n eCyD1,o rL32 construct and SYBR
Green PCR master mix followed by pipetting into an ABI Prism
96-well optical reaction plate (Applied Biosystems). The
sequences of the primers are shown in Supplementary Table
S2. The qPCR reaction was performed in the 7300 Real-Time
PCR System from Applied Biosystems using the following
cycle program: 40 cycles of 951C for 15s and 601Cf o r1m i n .
Results obtained from the PCR reaction were analyzed by
comparative Ct analysis to determine the relative amount of
murine TNF-a or CyD1 cDNA in the samples.
Determination of tissue murine cytokine expression levels by
ELISA. For subsequent ELISA, samples of the entire large
intestine were homogenized in lysis buffer (1 M TRIS, pH 7.4;
0.5 M EDTA, pH 8.0; 5 M NaCl, 10% (w/v) Brij, 10% (v/v)
Tween 20, and proteinase inhibitor) on ice for extraction of
proteins from the tissue samples. Protein-containing
supernatant was separated by centrifugation at 13,000g for
30min at 41C and stored at  701C until analysis. Changes
in the concentration of a series of cytokines and chemokines
(TNF-a, IL-1a, IL-1b, IL-2, interferon (IFN)-g, IL-5, IL-6,
IL-17, monocyte inﬂammatory protein (MIP)-1a, monocyte
chemotactic protein-1, and granulocyte macrophage colony-
stimulating factor) in the large intestine of colitis-induced
Balb/c mice were measured with the Q-Plext Mouse
Cytokine Screen ELISA (Quansys Biosciences, Logan, UT)
according to the manufacturer’s protocol. Luminescence
intensity of each sample was measured and the
concentration of each cytokine was analyzed with a ﬁve-
parameter curve ﬁtting using the Q-Viewt software
(Quansys Biosciences). Resulting cytokine and chemokine
concentrations were normalized against the total protein
content of each individual sample as determined by
bicinchoninic acid assay (Pierce, Rockford, IL). Values
are expressed as pictogram (pg) of murine cytokine or
chemokine expressed per mg of total protein content of each
sample and represent mean±s.d. of 4–6 mice.
Western blot analysis. Western blot analysis was conducted
by separation of total cellular lysates (150mg) using
4–20% sodium dodecyl sulfate–PAGE and subsequent
electrophoretic transfer of proteins to a polyvinylidene
ﬂuoride membrane. Membranes were blocked with
universal blocking buffer (Fisher Scientiﬁc, Pittsburgh, PA)
for 15min at room temperature and probed overnight at 41C
with CyD1 monoclonal antibody or b-actin antibody serving
as a control (Cell Signaling Technology, Danvers, MA). After
washing, membranes were incubated with the appropriate
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1h at room temperature followed by immunodetection using
the enhanced chemiluminescence technique (Pierce).
Histological analysis of tissue sections by haematoxylin and
eosin staining. Tissue samples were evaluated for mucosal
architectural change, cellular inﬁltration, inﬂammation,
goblet cell depletion, and signs of epithelial regeneration by
using light microscopy of haematoxylin and eosin survey
staining.
42,43 These values were used to assess the degree
of mucosal damage and repair in treatment and control
groups. Tissue samples harvested from distal regions of the
non-inﬂamed/inﬂamed colon were stored in 10% formalin
solution at 41C for 7 days to ensure complete penetration
and ﬁxing of the tissue. After removal from formalin solution,
samples were washed with phosphate-buffered saline and
transferred to 30% (w/v) sucrose solution for 2 days to
protect from freezing damage in preparation of tissue for
cryosectioning. Tissue sections with a thickness of 7mm
were stained with haematoxylin and eosin according to the
protocols supplied by the manufacturer, followed by imaging
using bright-ﬁeld microscopy (Olympus BX51TRF, Olympus
America, Center Valley, PA).
Determination of tissue myeloperoxidase (MPO) activity.
Tissue MPO activity was detected with the FluoroMPO assay
purchased from Cell Technology (Mountain View, CA).
In preparation of this, tissue samples were minced in
hexadecyltrimethylammonium bromide buffer (0.5% in
50mM phosphate buffer) on ice and homogenized. The
homogenate was sonicated, subjected to a freeze–thaw
cycle, and centrifuged at 10,000r.p.m. for 3min. A certain
known amount of the tissue lysate supernatant was
combined with the detection mix containing H2O2, a non-
ﬂuorescent detection reagent, and 1  assay buffer. The
detection reagent was oxidized in the presence of hydrogen
peroxide and MPO to produce its ﬂuorescent analog, which
was measured at an excitation wavelength of 530nm and
emission of 590nm. Reported values were normalized to mg
of total protein content of the sample.
Statistical data analysis. All data shown are represented
as mean±s.d. Statistical differences between DSS control
and TNF-a, CyD1, or TNF-a/CyD1 combination NiMOS, and
between scramble sequence-containing NiMOS TNF-a,
CyD1, or TNF-a/CyD1 combination NiMOS groups were
determined on both time points using a T-test with separate
variance estimates. P values below 0.05 were considered
signiﬁcant; and only signiﬁcant differences are shown for the
sake of clarity.
RESULTS
Acute colitis was induced in female Balb/c mice (6–8 weeks)
by addition of 3.5% (w/w) dextran sodium sulfate (DSS) in
theirsolesourceofdrinkingwaterforthedurationofthestudy,
whereas one control group (n¼8) received regular tap water
throughout the course of the study. This model has been most
frequently used and was ﬁrst discussed by Okayasu et al.
44 in
1990becauseofitsconvenient inductionofthedisease, lower
mortality risk, and deﬁned beginning.
42 Simultaneously, three
doses of blank or siRNA-encapsulating NiMOS (1.2mg/kg of
body weight) were orally administered to groups of four to ﬁve
animals every other day starting on day 3 of the study
following an overnight fasting period, as food in the stomach
and other sections of the gastrointestinal tract is known to
interfere with dosing and analysis upon administration of the
formulations. RNA silencing of TNF-a and CyD1, and its
effects on the severity and symptoms of the acute colitis
disease model were evaluated at predetermined time points
of 3 and 5 days after the last oral administration of the
treatment. Four to ﬁve animals per time point and group were
killed, their large intestines were surgically removed and
washed to prepare for subsequent analysis of the tissue,
including assessment of cytokine proﬁle, mRNA expression
levels of TNF-a and CyD1, and histological analysis as
well as evaluation of therapeutic efﬁcacy of each treatment.
As shown previously, TNF-a expression was at its highest
level on day 10 of the study before and after which the
values were signiﬁcantly decreased.
32 On the basis of these
results, day 10 was chosen as the ﬁrst time point for
evaluation of RNA silencing and its effects on the severity
and symptoms of the acute colitis disease model as
differences between controls and treatment were expected
to be at maximum at this time point. A second time point was
chosen to be 5 days after the last oral administration (day 12),
where DSS control groups were alive, and to see whether the
effect of RNA silencing was still persistent. Relevant controls
consisted of untreated animals (healthy group and DSS
control, n¼4) and groups treated the same as test groups
receiving active/silencing NiMOS (n¼5), but were instead
orallyadministeredwithblank/unloadedorinactive/scrambled
NiMOS (n¼5).
TNF-a and CyD1 RNA silencing and protein
expression. Real-time qPCR (qPCR) was used to conﬁrm
levels of TNF-a or CyD1 upon multiple administration of
siRNA-encapsulating NiMOS with sequences active in the
cleavage of the selective mRNA. Tissue samples were taken
from the same region of the colon across all groups of
animals for consistency. Overall, lowest mRNA expression of
both TNF-a and CyD1 was observed in the healthy control
group on day 10 of the study (Figure 2a) and described as
the baseline level. At this time point, TNF-a mRNA levels
were reduced when compared with levels observed in
animals of the DSS control, blank, scrambled, and CyD1
NiMOS group. Combined siRNA administration had a
stronger effect on downregulation of mRNA expression
than administration of single siRNA as evidenced by the
lower TNF-a level achieved. Elevated levels were observed
in groups treated with CyD1 NiMOS, indicating the speciﬁcity
of the TNF-a siRNA to cause downregulation only in that
particular group. However, inactive and CyD1 NiMOS led to
upregulation of TNF-a mRNA compared with the remaining
test and control groups. On the second time point, all three
silencing groups were signiﬁcantly reduced in comparison
with all control groups (untreated or mock treated).
As shown in Figure 2b, oral administration of CyD1 NiMOS
resulted in substantial downregulation of CyD1 mRNA
expressionatboth timepointscomparedwithall othergroups.
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a slightly higher expression of CyD1 mRNA potentially due to
a dilution effect of CyD1 siRNA compared with CyD1 NiMOS
alone.
An ELISA was performed on intestinal tissue lysates for
quantiﬁcation of TNF-a, to identify a potential correlation of
mRNA levels and posttranslational protein expression
(Figure 2c). It is noteworthy that treatment with CyD1 NiMOS
led to a signiﬁcant decrease in TNF-a levels in these samples
on the ﬁrst test day; a very low value of 49fg/mg total protein
was detected, equaling a 36-fold reduction compared with the
healthy control group. On day 12, protein levels were also
reduced in this group compared with all other animals tested,
followed by the dual siRNA NiMOS group. The control groups
consisting of animals administered with blank NiMOS or
scrambled siRNA-encapsulated NiMOS in addition to the
untreated DSS control group showed no signiﬁcant difference
in the TNF-a expression pattern at both time points, whereas
elevated levels of the protein were observed on day 12 in all
colitis-bearing control groups. Administration with TNF-a
NiMOS resulted in a slight decrease in protein expression
on day 10, which was shown before
32 and correlates with the
mRNA proﬁle. Combined siRNA treatment led to stronger
reduction in TNF-a expression than administration with TNF-a
siRNA alone, which can be attributed to the effect of CyD1
silencing that was signiﬁcantly more potent than that of TNF-a
silencing. Furthermore, statistically signiﬁcant differences
were observed between dual siRNA NiMOS and scrambled
NiMOS groups in both time points.
CyD1 protein expression was detected by western blotting of
intestinal cell lysates (Figure 2d). On day 10 and 12, much less
CyD1 was detected in the CyD1 NiMOS-treated group in
comparison with all controls as well as the TNF-a and
combination siRNA NiMOS group, indicating the speciﬁcity of
the siRNA and success of RNAi. Lower detection of CyD1 was
also observed in both remaining test groups compared with the
controls, which slightly diminished on day 12. b-Actin loading
controls revealed similar intensity of the bands in all groups
verifying the proper loading of the samples into the wells.
Transfection efﬁciency. The cytokine proﬁle of a variety of
markers was assessed to better understand the occurring
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Figure 2 mRNA and protein expression proﬁles in control and short interfering RNA (siRNA)-treated mice. Murine tumor necrosis factor-a (TNF-a) and murine cyclin D1
(CyD1) expression upon oral administration of three doses of nanoparticles-in-microsphere oral system (NiMOS; blank or encapsulating inactive (scrambled) siRNA, TNF-a
siRNA, CyD1 siRNA, combined TNF-a/CyD1 siRNA) to animals under continuous dextran sulfate sodium (DSS) exposure. Each control or test group consisted of four to ﬁve
animals.GenemRNAlevelsweremeasuredbyreal-timequantitativePCRanalysis,normalizedagainstL32anddepictedasrelativegeneexpressionof(a)murineTNF-aand
(b) murine CyD1 mRNA performed on samples of the large intestines. Repeated oral administration of the respective siRNA and combination therapy loaded NiMOS led to a
reducedmRNAexpressionofTNF-aandCyD1,respectively,comparedwithDSS controlanimalsoranimalstreatedwithunloadedor scrambled siRNAloadedNiMOSstudy.
(c) Quantitative determination of TNF-a in total cell lysates from colonic tissue by enzyme-linked immunosorbent assay. Levels of the protein were signiﬁcantly reduced in
CyD1 NiMOS groups on day 10 compared with all remaining treatment and control groups including the healthy control group. On day 12, TNF-a levels were reduced in all
active siRNA groups compared with the inactive (scrambled) siRNA and blank NiMOS as well as untreated and control and DSS control groups. (d) Western blot of total cell
lysates from intestinal tissue for determination of CyD1 with the loading control b-actin. Administration of CyD1 siRNA-loaded NiMOS led to reduction in CyD1 expression
comparedwiththeremainingcontrolandtestgroupsondays10and12,whereasproteinexpressionwasreducedinTNF-a/CyD1combinedsiRNANiMOSonlyonday10and
showeda slight increase on day 12. Values are represented as mean±s.d. (n¼4–5). Control¼naı ¨ve, no colitis; DSS control¼colitis, no treatment;blank NiMOS¼colitis,
blank microspheres; scramble NiMOS¼colitis, scrambled siRNA-containing microspheres; CyD1 NiMOS¼colitis, CyD1 siRNA-containing microspheres; TNF-a
NiMOS¼colitis, TNF-a siRNA-containing microspheres; TNF/CyD1 NiMOS¼colitis, microspheres containing and combination of both TNF-a and CyD1 siRNA. *Po0.05,
vs.Scramble,Statisticalcomparison wasperformedondatasetsofDSScontrolvs.TNF-a,CyclinD1,andTNF-a/CyclinD1 combinationNiMOS,andbetweenTNF-a,Cyclin
D1, and TNF-a/Cyclin D1 combination vs. Scramble NiMOS group. Only signiﬁcant differences are shown.
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treatment group upon oral administration of three doses of
blank, scrambled, or silencing NiMOS. For this purpose, cell
lysates prepared as described below were assayed using
a Q-Plext Mouse Cytokine Screen ELISA (Quansys
Biosciences) according to the manufacturer’s guidelines,
and results are expressed as pg per mg of total protein
content of each sample (Figure 3). Similarly, as previously
mentioned, administration of CyD1 NiMOS led to a signiﬁcant
downregulation of cytokine expression on day 10, ranging
from 2.3-fold to almost 52-fold reduction compared with even
the healthy control group, which generally exhibited the
lowest expression of the cytokines of all animals tested,
except in the case of IFN-g on day 12. On day 12, an overall
increase in cytokine concentration was observed in the CyD1
NiMOS group, whereas expression levels were still below
that of remaining colitis-bearing control and test animals.
Treatment with TNF-a NiMOS caused a signiﬁcant decrease
in expression of IFN-g, IL-1a, IL-5, and the chemokines
monocyte chemotactic protein-1 and MIP-1a compared
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Figure 3 Colonic cytokine and chemokine proﬁles. The cytokine expression proﬁle upon oral delivery of cyclin D1 (CyD1), tumor necrosis factor-a (TNF-a), or a
combination of both short interfering RNA (siRNA) encapsulated in nanoparticles-in-microsphere oral system (NiMOS) was determined using a chemiluminescent enzyme-
linked immunosorbent assay Q-Plex Mouse Cytokine Screen (Quansys Biosciences). Concentrations of the cytokines (a) interferon (IFN)-g,( b) interleukin (IL)-1a,( c) IL-1b,
(d) IL-2, (e) IL-5, (f) IL-6, (g) IL-17 and pro-inﬂammatory chemokines (h) monocyte chemotactic protein (MCP)-1, (i) monocyte inﬂammatory protein (MIP)-1a, and
(j) granulocyte macrophage colony-stimulating factor (GMCSF) in the large intestine are shown. Administration of CyD1 NiMOS led to a signiﬁcant reduction in protein
expression both time points tested compared with the remaining groups. The effect of combined TNF-a/CyD1 NiMOS and TNF-a was less pronounced, but led to decreased
proteinlevels incomparisonwith controlgroups.Valuesexpressedasmean±s.d. (n¼5).
DPo0.05, vs.DSS control;
DDPo0.01,vs. DSScontrol;*Po0.05,vs. Scramble;
**Po0.01, vs. Scramble; Statistical comparison was performed on data sets of DSS control vs. TNF-a, Cyclin D1, and TNF-a/Cyclin D1 combination NiMOS, and between
TNF-a, Cyclin D1, and TNF-a/Cyclin D1 combination vs. Scramble NiMOS group. Only signiﬁcant differences are shown.
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Clinical and Translational Gastroenterologywith colitis-bearing controls on both days, and also lower
concentrations of IL-1b, IL-17, and granulocyte macrophage
colony-stimulating factor on day 12, which was less
pronounced compared with the CyD1 NiMOS group in both
cases. Overall, a signiﬁcant reduction in expression of pro-
inﬂammatory markers was recorded on the second time point
in this group compared with all colitis-bearing control
animals, indicating success of the treatment in a slightly
delayed manner. Combined administration of TNF-a and
CyD1 siRNA led to a decline in IL-1a, IL-1b, IL-2, IL-5, IL-17,
monocyte chemotactic protein-1, MIP-1a, and granulocyte
macrophage colony-stimulating factor expression on day 10
and 12, and in IFN-g and IL-6 on day 12 compared with the
DSS control, mock-treated, and TNF-a NiMOS-treated
animals. Results show that the effect of combined TNF-a/
CyD1 NiMOS resulted in a stronger, more effective decrease
in expression compared with single siRNA treatment of
TNF-a alone, but less powerful than the effect of CyD1
administration potentially due to dilution effect with TNF-a
NiMOS.
Colonic tissue histopathology. An important aspect to
investigate feasibility and efﬁcacy of the study involves
evaluation of changes in tissue histology of each test group
upon induction and treatment of inﬂammation. Bright-ﬁeld
images of haematoxylin and eosin survey stained tissue
sections (original magniﬁcation  10 and  40) from
each control and test group are shown in Figure 4. Tissue
from healthy control mice served as a baseline control for
comparison purposes as it showed no signs of abnormal
tissue architecture or inﬂammatory inﬁltration. In comparison
with this, tissue sections from colitis-bearing control animals
exhibited clear signs of inﬂammation, including inﬁltration
with leukocytes and gross destruction of normal mucosal
structure, such as goblet cell depletion, ulcerations, and
membrane thickening, on day 10 and 12. Quite the opposite
was observed in tissue from test groups receiving CyD1,
TNF-a, or combined TNF/CyD1 silencing NiMOS. Here, the
degree of inﬂammation signiﬁcantly diminished showing
signs of regeneration and tissue morphology similar to the
healthy baseline group on both time points tested.
Macroscopic evaluation of anti-inﬂammatory therapeutic
efﬁcacy. The experimental design of the study is illustrated
in Figure 5a. Changes in body weight of colitis-induced
mice, colon length, and MPO were evaluated after
administration of various treatments in comparison with the
control (Figure 5b–d). The dips in the weight loss curve
(Figure 5c) correspond to the time points of oral
administration following the overnight fasting period. As
fasting caused a substantial weight loss of B10% across
all animal groups, NiMOS formulations were administered
every other day to allow for a certain degree of weight
normalization to occur. In the healthy control group, the
weight stabilized after the last fasting period, so that it leveled
out at the original body weight, measured at the beginning of
the study. On the other hand, the DSS control group as well
as animals receiving blank or scrambled siRNA sequence
NiMOS exhibited a severe and relative quick weight loss of
28.6, 24.1, and 33.4% of original body weight on day 12.
Additionally, a considerable number of animals demonstrated
the classical features associated with acute colitis, including
gross rectal bleeding, loose and bloody stools in addition to a
general lethargic appearance and scrubby fur. In contrast,
test groups administered with CyD1, TNF-a, and TNF-a/
CyD1 NiMOS showed signiﬁcantly less change in their
original body weight with respective values of 14.5, 8.7,
and 8.8% at the end of the study. Furthermore, their
overall health seemed much improved over the colitis-
bearing control groups closely resembling healthy animals,
with no apparent signs of colitis. These observations are in
good agreement with the histological evaluation described
above.
To further evaluate therapeutic efﬁcacy of the treatment,
colon lengths were measured and are reported in Figure 5b.
Colons were about 45, 35, and 45% shorter in DSS control,
blank, and scrambled NiMOS-treated groups, respectively,
compared with the healthy control on day 10, which measured
a length of B10cm. On the second time point, the length
slightly increased in these groups; reduction ranged now
between 30 and 41%. In animals treated with silencing
NiMOS, an overall increase in colon length compared with
colitis control groups was recorded with colon tissue B22%
shorter than what was measured in healthy animals. On day
12, these values further diminished to about 13% in all test
groups and closer to the baseline of healthy mice.
A further marker of inﬂammatory inﬁltration was assessed
by determination of MPO activity as its occurrence is directly
related to presence and activation of neutrophil granulocytes.
Overall, administration of active siRNA-containing NiMOS led
to a reduction in MPO activity to around 1mU/ml per total
protein content in all three test groups on day 10 with a slight
increase up to 1.5mU/ml on day 12 (Figure 5d). Measured
activities in these animals were lower at both test times
compared with all colitis-bearing controls and healthy control
mice, where an activity of 1.6 and 1.8mU/ml was detected per
total protein content on day 10 and 12, respectively. Highest
values of 2.6 mU/ml were observed in blank NiMOS-treated
animals on day 10, which was reduced on the second time
point. DSS control and inactive siRNA sequence-containing
NiMOS-treated groups had comparable activities on day 10,
and exhibited reduction and increase, respectively, as the
study progressed.
DISCUSSION
Current IBD treatment still faces major limitations associated
with its efﬁcacy and safety. Thus, new biological therapeutic
strategies are increasingly investigated.
4,10 This present
work shows the promise of a novel IBD treatment option by
combining the positive aspects of RNAi with the safety of a
biodegradable polymeric delivery system to facilitate a
localized treatment via oral administration of siRNA rather
than using the traditional systemic approach as reported
before.
15,21 Mucosal administrationincluding oraldeliveryhas
a therapeutic potential for a multitude of diseases and poses
several advantages over the traditional method including no
relative dilution of the active component (e.g., in the blood
stream) due to local delivery enabling the use of lower and
fewer doses resulting in overall increased efﬁcacy while
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suchasviarectalroutesmightfailbecauseofnon-feasibilityin
casesofseverediarrheaassociatedwithIBDinadditiontothe
discomfort the disease already causes. Ideally, mucosal
therapies should involve a deﬁnite mechanism of action with
a fast onset and long-lasting effect even after a single
administration. As it has many of these characteristics, siRNA
has the potential to fulﬁll this; while duration is dependent on
the potency of the siRNA molecule and potential destruction
inside the cells.
19 However, to fully realize the therapeutic
capability of siRNA, suitable delivery systems maximizing
cell penetration and prolonged intracellular gene silencing
have to be developed. Owing to rapid siRNA degradation,
stability and effective delivery still pose great challenges,
45 so
that development of suitable delivery vehicles are crucial in
the success of gene silencing by siRNA.
Control
Goblet cells 
DSS Control
Cell Infiltrations 
Blank NiMOS 
Scramble NiMOS
CyD1 NiMOS
TNF-  NiMOS TNF-  NiMOS
TNF- / CyD1 NiMOS TNF- / CyD1 NiMOS
10x 40x
Day 10
10x
Control
DSS Control
Blank NiMOS
Scramble NiMOS
CyD1 NiMOS
Day 12
40x
Figure 4 Microscopic evaluationof colonic tissuehistopathology. Bright-ﬁeldimages of haematoxylin and eosin stained sections of the colon harvestedfrom each control
and test group. Images are shown at magniﬁcations of  10 and  40 from tissue cryosections obtained on day 10 and day 12 of the study. Sections from the ﬁrst control
group show normal and healthy colon tissue. Intestinal tissues from the dextran sulfate sodium (DSS) control group, the group treated with blank and scrambled short
interferingRNA(siRNA)nanoparticles-in-microsphereoralsystem(NiMOS)showedasevereinﬁltrationofwhitebloodcells,abnormalmucosalstructure,andacertaindegree
of goblet cell depletion. Tissue from the group receiving tumor necrosis factor-a (TNF-a), cyclin D1 (CyD1), or combined TNF/CyD1 silencing NiMOS showed signs of
regeneration and exhibited a tissue architecture more closely resembling that of healthy tissue in the normal control group. Occurrence of goblet cells is indicated by red
arrows; cell inﬁltration and abnormal tissue histology is indicated by black arrows.
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oral siRNA delivery.
22 Hereby, a delivery system based on
b-1,3-D-glucan shells originating from baker’s yeast was
employed after it had undergone a lengthy procedure
involving extractions, puriﬁcation, and loading steps, which
enabled the researchers to achieve reduced levels of
systemic kinase kinase kinase kinase 4 (Map4k4) in macro-
phages for attenuation of inﬂammatory responses.
Inthis presentstudy,amulticompartmental, biodegradable,
and biocompatible polymer-based nanoparticles-in-micro-
sphere delivery system was utilized to encapsulate and safely
deliver siRNA within its hydrophilic nanoparticulate core.
Type b gelatin was chosen as a matrix for nanoparticles
because it promotes physical entrapment of nucleic acids
within rather than electrostatic complexation or adsorption on
its surface, which could pose difﬁculties in the release of the
nucleic acids, and potentially reduce its efﬁcacy. Release of
the payload carrying nanoparticles occurs over time at
inﬂamed sites in the intestine via controlled degradation of
the outer layer by action of lipases abundantly present at this
location after which they can be endocytosed by enterocytes
or other cells at these sites.
28,30 We have successfully
incorporated multiple target siRNAs within NiMOS followed
by oral administration to DSS-induced colitis mice and
evaluation of its potency in silencing of genes involved
in inﬂammation. Speciﬁcally, TNF-a was chosen as the
primary target cytokine because of its crucial role in the
pathogenesis of IBD as the central mediator of inﬂammation.
Furthermore, its pharmacological reduction was demon-
strated to diminish severity of the disease in animal models
and humans.
12 However, it is noteworthy that modulation of
DSS-induced colitis by TNF-a reduction is still surrounded by
a certain degree of ambiguity. Some studies ascribe a
protective role to TNF-a in the initial phase of acute DSS
colitis,
46 other studies interested in siRNA-mediated gene
silencing have reported decreased severity of inﬂammation
after downregulation of this protein.
19,21 The central hypoth-
esis is that downregulation of TNF-a can result in lower levels
of other pro-inﬂammatory markers, which can help to restore
the delicate balance between pro- and anti-inﬂammatory
cytokines to allow for alleviation of symptoms and severity of
the disease.
Analysis of qPCR on both time points showed decreased
levels of murine TNF-a and CyD1. On day 12, mRNA
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administration). Values are expressed as mean±s.d. (n¼4–5).
DPo0.05, vs. DSS control; *Po0.05, vs. Scramble; **Po0.01, vs. Scramble; Statistical comparison was
performedondatasetsofDSScontrolvs.TNF-a,CyclinD1,andTNF-a/CyclinD1combinationNiMOS,andbetweenTNF-a,CyclinD1,andTNF-a/CyclinD1combinationvs.
Scramble NiMOS group. Only signiﬁcant differences are shown.
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was smaller than levels recorded in the healthy control group,
which can be attributed to the speciﬁc RNA silencing effect of
NiMOS, and was not observed in remaining colitis-bearing
groups. However, on day 12, an overall decrease in TNF-a
mRNA expression was seen in all colitis-bearing groups
potentially because of a complex interaction of pro-and anti-
inﬂammatory cytokines causing compensatory reactions due
to induction of colitis. Results from the ELISA showed a small
delay in TNF-a silencing as evidenced by slightly decreased
protein expression on day 10 compared with control groups.
Muchdecreasedexpression of TNF-a and a multitude ofother
pro-inﬂammatorycytokines(e.g., IL-1a,IL-1b,IL-5,and IL-17)
and chemokines (e.g., monocyte chemotactic protein-1, MIP-
1a, and granulocyte macrophage colony-stimulating factor),
measured on day 12 and compared with colitis-bearing
controls, indicate the success of TNF-a and CyD1 silencing
and suggest high potential of both CyD1 and TNF-a siRNA
NiMOS for oral administration. The delayed response also
reﬂects the speciﬁcity of siRNA encoding for TNF-a,a s
immune reaction for other markers needs time to occur. The
increaseinmRNAtranscriptforbothproteinsinthescrambled
NiMOS group can potentially be ascribed to an unspeciﬁc
immune response elicited by NiMOS and/or inactive siRNA
sequence itself. Owing to the fact that the siRNA sequence
was in an unmodiﬁed state, it could likely elicit an immune
response. To avoid such an off-target effect, modiﬁed and as
such non-immune modulating siRNA should be included in
future studies as a control.
Chemokines are indicators regulating cell inﬁltration at
disease sites, which directly contribute to inﬂammatory
responses. Previous studies demonstrated that systemic
administration of MIP-1a can signiﬁcantly exacerbate colitis
in mouse models,
47 so that decrease in levels of MIP-1a,a s
observed in TNF-a NiMOS groups, suggests an improvement
of the disease. Overall, it seems possible that lower
expression of pro-inﬂammatory cytokines due to downregula-
tion of TNF-a and CyD1 can result in alleviation of inﬂamma-
tion at the disease site. This is also in very good agreement
withthesmaller degreeofweightloss,increasedcolonlength,
lower level of tissue MPO activity, and regenerative tissue
histology observed in this group. Simultaneously, elevated
levels of pro-inﬂammatory cytokines in combination with
severeweightlossandpathologicaltissuehistology,including
loss of goblet cells, inﬁltration, and destruction of regular
mucosal architecture, were detected in non-treated groups
and animals treated with blank and scrambled NiMOS.
Because of its upregulation in a number of inﬂammatory
sites, such as in chronic pancreatitis
38 and inﬂamed intestines
in IBD,
21 CyD1 was chosen as the other target for RNA
silencing. The incentive of the study is based on the other
hypothesis that encapsulation of multiple siRNA targets, e.g.,
TNF-a and CyD1, into NiMOS likely result in an even more
potent effect on downregulation of pro-inﬂammatory cyto-
kines, so that combined administration can multiply efﬁcacy of
the treatment. Real-time PCR analysis showed signiﬁcantly
reduced levels of CyD1 mRNA expression in CyD1 NiMOS
animals on both time points tested compared with all other
control or test groups indicating the potency in RNA silencing.
Furthermore, the effect of CyD1 silencing was much stronger
and even overpowering that of TNF-a silencing, leading to a
substantial decrease in expression of pro-inﬂammatory
cytokines and chemokines on both time points tested.
Therapeutic efﬁciency was improved in this group as well as
evidenced decrease in weight loss, increased colon length,
lower level of MPO, and a tissue histology closely resembling
that of healthy control groups.
Furthermore,resultsfromqPCRforTNF-ashowthatsiRNA
encoding for CyD1 speciﬁcally silences CyD1,a sn oTNF-a
RNA reduction was recorded on day 10. The sequence
speciﬁcity of RNA silencing with the aid of siRNA particularly
encoding for CyD1 or TNF-a is demonstrated by the fact
that no silencing of the respective RNA was observed in other
control groups. Additionally, the scrambled sequence is
irrelevant or inactive as no reduction, aberrant upregulation,
or non-speciﬁc interferon response was elicited. Although
downregulation of pro-inﬂammatory markers in the TNF-a
NiMOS group was slightly delayed, there was an apparent
immediate effect in the CyD1 NiMOS group, which demon-
strates the potency of CyD1 silencing.
It is noteworthy that combined siRNA treatment caused a
strongerdownregulation ofTNF-a and otherpro-inﬂammatory
cytokines than administration with TNF-a siRNA alone, which
is a further attribute to the potency of CyD1 silencing.
However, this effect was not as pronounced as CyD1
administrationalone,whichresultedinthestrongestreduction
of pro-inﬂammatory markers tested and can be ascribed to a
potential dilution effect in the combined treatment containing
the same overall amount as the single siRNA. In future
studies, more siRNA will be incorporated to maximize and
further improve the effect of the dual treatment. Moreover, it
can be concluded that the effect of CyD1 silencing was more
potent than that of TNF-a indicating the important role of
the molecule in inﬂammation and the potential for further
exploration as a target for future therapy strategies. As
mentioned before, the nanoparticle in microsphere oral
delivery system and the non-modiﬁed siRNA sequence used
in this study might result in an immune-modulatory effect,
which can affect some of the results. Therefore, it is an
important control in this study. Although this system needs
further improvement and optimization, results presented with
this study show the promising nature of NiMOS as a
therapeutic treatment option for IBD. Other future projects
will involve testing of different time points to study the duration
of the RNA silencing effect and addition of targeting moieties
to further optimize and improve delivery and efﬁcacy.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
| Inﬂammatory bowel disease (IBD) is a chronic
relapsing condition involving inﬂammation of the
lower gastrointestinal tract with unknown etiology.
| Current treatment options involve palliative therapy
(i.e., immunosuppressive or anti-inﬂammatory
drugs), biological response modiﬁers (i.e., systemic
antibodies aimed at tumor necrosis factor-a (TNF-a)
and other pro-inﬂammatory markers known to have
a major role in the disease), and surgical removal of
the inﬂamed tissue.
| To date, the disease cannot be cured and no
treatment is self-sufﬁcient; and limitations in safety
and efﬁcacy promote development of novel
biological treatment offering the potential for
better treatment options.
WHAT IS NEW HERE
| A multicompartmental, biodegradable, and
biocompatible polymer-based nanoparticles-in-
microsphere delivery system was utilized for
encapsulated dual short interfering RNA (siRNA)
delivery targeting TNF-a and cyclin D1 to improve
treatment of IBD.
| Combined siRNA treatment caused a stronger down-
regulation of TNF-a and other pro-inﬂammatory
cytokines than administration with TNF-a
siRNA alone.
| Signs and symptoms of colitis were less severe
in animals exposed to dual siRNA treatment
compared with single administration of TNF-a as
shown on a macroscopic and microscopic level.
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